Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.
J Clin Oncol
; 41(4): 715-723, 2023 02 01.
Article
in En
| MEDLINE
| ID: mdl-36706735
Full text:
1
Database:
MEDLINE
Language:
En
Journal:
J Clin Oncol
Year:
2023
Type:
Article